TY  - JOUR 
AU  - Facultad de Ciencias Economicas y Empresariales
AU  - Tavara, B.
AU  - Garrido, M.L.
AU  - Rodríguez, Z.
AU  - Rojas, M.
AU  - López, L.
AU  - Medina, S.
AU  - Ponte, C.
AU  - Lopez, A.
AU  - Sanchez, E.
AU  - Pedraza, M.
AU  - Viñals, P.
AU  - López, M.
AU  - Alonso, D.
AU  - Rodríguez, A.
AU  - Davila, E.
AU  - Castañon, C.
AU  - De Sande, L.M.
AU  - Nieto, B.
AU  - Vallejo Pascual, María Eva
AU  - Rodríguez, J.d.I.R.
AU  - Garcia Palomo, A.
AU  - Diz Taín, P.
AU  - Métodos Cuantitativos para la Economía y la Empresa
DA  - 2022
SN  - 1556-0864
UR  - https://hdl.handle.net/10612/18409
AB  - [EN] Introduction:  Durvalumab received EMA approval as consolidation
therapy (CT) for unresectable stage III NSCLC with PD-L1 _1% and
who did not have progression after CRT. Our objective was to analyze
in real clinical practice the effectiveness...
LA  - eng
PB  - Elsevier
KW  - Estadística
KW  - Medicina. Salud
KW  - Durvalumab
KW  - Pacific
KW  - Real world data
TI  - EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?
DO  - 10.1016/J.JTHO.2022.07.484
T2  - Journal of Thoracic Oncology
VL  - 17
M2  - S283
ER  -